Oxaliplatin

Oxaliplatin is a platinum-based chemotherapy drug that has shown promise in treating various types of cancer. This article explores the use of Oxaliplatin in clinical trials, focusing on its effectiveness, potential side effects, and combinations with other treatments for different cancer types.

Table of Contents

What is Oxaliplatin?

Oxaliplatin is a powerful chemotherapy drug used in the treatment of various types of cancer. It belongs to a class of medications known as platinum-based antineoplastic agents. Oxaliplatin works by damaging the DNA in cancer cells, which prevents them from dividing and ultimately leads to their death[1].

This medication is also known by other names, including:

  • SR96669[2]
  • PLEOXTIN (645402430)[3]

What Conditions Does Oxaliplatin Treat?

Oxaliplatin is primarily used to treat several types of cancer, including:

  • Colorectal Cancer: This is the most common use of Oxaliplatin, particularly for metastatic colorectal cancer (cancer that has spread to other parts of the body)[4].
  • Esophageal Cancer: Oxaliplatin is used in advanced stages of esophageal cancer[1].
  • Gastric (Stomach) Cancer: It’s used in combination with other drugs for treating stomach cancer[5].
  • Rectal Cancer: Oxaliplatin is part of treatment regimens for locally advanced rectal cancer[6].
  • B-cell Lymphomas: In some cases, Oxaliplatin is used to treat certain types of lymphomas[7].

How is Oxaliplatin Administered?

Oxaliplatin is typically administered through intravenous (IV) infusion, which means it’s given directly into a vein. The dosage and frequency can vary depending on the specific condition being treated and the patient’s overall health. Here are some common administration methods:

  • A typical dose is around 85-130 mg per square meter of body surface area[1].
  • It’s often given as a 2-hour infusion every 2 or 3 weeks[4].
  • In some cases, it may be administered through hepatic arterial infusion, which means it’s delivered directly to the liver. This method is sometimes used for liver metastases from colorectal cancer[8].

Oxaliplatin in Combination Therapies

Oxaliplatin is frequently used in combination with other chemotherapy drugs to enhance its effectiveness. Some common combination therapies include:

  • FOLFOX: This regimen combines Oxaliplatin with 5-Fluorouracil (5-FU) and Leucovorin. It’s commonly used for colorectal cancer[2].
  • FOLFOXIRI: This more intensive regimen adds Irinotecan to the FOLFOX combination. It’s used in some cases of metastatic colorectal cancer[6].
  • Oxaliplatin with S-1: This combination is sometimes used in gastric cancer treatment[3].
  • Oxaliplatin with Capecitabine: Another combination used in colorectal cancer treatment[9].

Potential Side Effects

Like all chemotherapy drugs, Oxaliplatin can cause side effects. It’s important to discuss these with your healthcare provider. Some potential side effects include:

  • Neuropathy: This is a common side effect that can cause tingling or numbness in hands and feet[2].
  • Nausea and vomiting
  • Fatigue
  • Diarrhea
  • Decreased blood cell counts, which can increase the risk of infection or bleeding

Current Research and Developments

Researchers continue to study Oxaliplatin to find new ways to use it effectively and minimize its side effects. Some areas of ongoing research include:

  • Neoadjuvant therapy: Using Oxaliplatin before surgery in certain cancers to shrink tumors[5].
  • Combination with targeted therapies: For example, combining Oxaliplatin with Bevacizumab in colorectal cancer treatment[2].
  • Use in other types of cancer: Exploring its effectiveness in cancers where it’s not commonly used[7].

Remember, while this information provides a general overview, your specific treatment plan may vary. Always consult with your healthcare provider for personalized information about your treatment with Oxaliplatin.

Aspect Details
Cancer Types Studied Colorectal, Gastric, Hepatocellular Carcinoma, Gastrointestinal, Breast
Common Combinations FOLFOX, XELOX, with Capecitabine, Gemcitabine, Bevacizumab
Administration Intravenous, often in cycles of 2-3 weeks
Primary Outcomes Overall Survival, Progression-Free Survival, Response Rate
Secondary Outcomes Safety Profile, Quality of Life, Time to Progression
Potential Side Effects Neuropathy, Fatigue, Nausea, Vomiting, Diarrhea, Blood Cell Count Changes
Special Considerations Renal Function, Pharmacokinetics, Immunogenicity

Ongoing Clinical Trials on Oxaliplatin

  • Study on the Safety and Effectiveness of Telisotuzumab Adizutecan and Drug Combination for Patients with Metastatic Colorectal Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Austria Czechia France Greece Italy Spain
  • Study on Cetuximab and Drug Combination for Patients with Metastatic Colorectal Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Italy Spain
  • Study on the Impact of Cisplatin and Drug Combination on Speech and Cognition in Cancer Patients

    Recruiting

    3 1 1 1
    Finland
  • Study on Regorafenib for Patients with Advanced RAS-Mutant Colorectal Cancer Using Regorafenib and Drug Combination

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Italy
  • Study of Simvastatin with Nivolumab and Oxaliplatin for Patients with Advanced Stomach or Esophageal Cancer with ARID1A Mutation

    Recruiting

    2 1 1 1
    Italy
  • Study on Chemotherapy for Patients with Resected Pancreatic Cancer Using FOLFIRINOX and Drug Combination

    Recruiting

    4 1 1 1
    Investigated Diseases:
    France
  • Study on Optimizing NALIRIFOX and 5-FU for Metastatic Pancreatic Cancer in First-Line Treatment and Exploring Ciprofloxacin in Second-Line Therapy

    Recruiting

    2 1 1
    Investigated Diseases:
    France
  • Study Comparing Rilvegostomig with Fluoropyrimidine and Trastuzumab Deruxtecan to Standard Treatment for Patients with HER2-positive Gastric Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Austria Belgium France Germany Hungary Italy +3
  • Study on the Safety and Effectiveness of Trastuzumab Deruxtecan and Drug Combination for Patients with HER2-Positive Gastric, GEJ, and Esophageal Cancer

    Recruiting

    1 1 1 1
    Germany Italy The Netherlands Poland Spain
  • Study of Trastuzumab Deruxtecan and Drug Combination for Patients with Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

    Recruiting

    3 1 1 1
    Austria Belgium Czechia France Germany Italy +6

Glossary

  • Oxaliplatin: A platinum-based chemotherapy drug used to treat various types of cancer, often in combination with other medications.
  • FOLFOX: A chemotherapy regimen that combines Oxaliplatin with 5-fluorouracil and leucovorin, commonly used in colorectal cancer treatment.
  • Capecitabine: An oral chemotherapy drug that is sometimes used in combination with Oxaliplatin, known by the brand name Xeloda.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall Survival (OS): The length of time from either the date of diagnosis or the start of treatment that patients are still alive.
  • Response Rate: The percentage of patients whose cancer shrinks or disappears after treatment.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Hepatocellular Carcinoma: The most common type of primary liver cancer.
  • Neuropathy: Nerve damage that can cause numbness, tingling, or pain, often a side effect of certain chemotherapy drugs like Oxaliplatin.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.

References

  1. https://clinicaltrials.gov/study/NCT00259402
  2. https://clinicaltrials.gov/study/NCT00988897
  3. https://clinicaltrials.gov/study/NCT02191566
  4. https://clinicaltrials.gov/study/NCT01163396
  5. https://clinicaltrials.gov/study/NCT00816543
  6. https://clinicaltrials.gov/study/NCT05253846
  7. https://clinicaltrials.gov/study/NCT01068392
  8. https://clinicaltrials.gov/study/NCT00695201
  9. https://clinicaltrials.gov/study/NCT02086656